Eisai Co., Ltd.
Lecanemab® Subcutaneous Injection 250 mg Pen, Notification of Approval in Japan
Subcutaneous formulation of lecanemab in Japan approved. Expanded at-home administration options are expected to improve treatment flexibility, with only a minor impact on the earnings guidance for the 2027 fiscal year.
Key Figures
- Unknown: Revenue, operating income, net income, etc. (financial metrics)
- Unknown: Concrete figures for cost savings from home administration implementation
- Unknown: Amounts and YoY changes in 2027 FY earnings guidance
AI要約
Overview of the News
Eisai announced that the subcutaneous formulation of the anti-amyloid beta protofibril antibody 'Leqembi®'—the subcutaneous injection 'Leqembi® subcutaneous 250 mg pen'—has been approved in Japan as a new route of administration. Subcutaneous dosing is once weekly, two pens (total 500 mg), enabling home administration, which is expected to shorten administration time and reduce medical resource use compared with IV administration.
Scope and Future Prospects
The approval targets early AD (MCI and mild dementia), and home self-administration will be possible after post-approval review and acceptance for insurance coverage. Data demonstrating equivalent efficacy and safety to IV administration is cited as the basis, and treatment pathway efficiency is expected.
Eisai Co., Ltd.
Company overview · Stock price · Financial data · All IR
